Chemotherapy and Drug Information

Farydak (panobinostat) now FDA-approved for multiple myeloma

Farydak (panobinostat) now FDA-approved for multiple myeloma

Drug is now sanctioned for people who have received at least two prior standard therapies.

Study identifies reasons for ibrutinib discontinuation in patients with chronic lymphocytic leukemia

Study identifies reasons for ibrutinib discontinuation in patients with chronic lymphocytic leukemia

About 10% of patients with chronic lymphocytic leukemia (CLL) treated with ibrutinib discontinued their therapy due to disease progression during clinical studies.

Patient beliefs about chemotherapy, cancer influence care choices at the end of life

Patient beliefs about chemotherapy, cancer influence care choices at the end of life

Patients with advanced cancer who believed chemotherapy might cure their cancer were more likely to receive chemotherapy.

Inherited gene variation helps explain drug toxicity in patients of East Asian ancestry

One tenth of younger leukemia patients of East Asian ancestry inherit a gene variation associated with lowered tolerance of an indispensable drug for acute lymphoblastic leukemia (ALL).

Hair dye use during chemotherapy

Hair dye use during chemotherapy

Is it safe to use hair dyes concurrently with chemotherapy?

Epigenetic drug boosts efficacy of chemotherapy in some lung cancers

Epigenetic drug boosts efficacy of chemotherapy in some lung cancers

An existing drug may assist patients with non-small cell lung cancer (NSCLC) that shows chemotherapy resistance.

Ibrance now FDA-approved to treat advanced breast cancer

Ibrance now FDA-approved to treat advanced breast cancer

Ibrance (palbociclib) has been approved by the U.S. Food and Drug Administration (FDA) for postmenopausal women with ER, HER2-negative metastatic breast cancer.

Assessing patency of an implanted port

Assessing patency of an implanted port

How should a fibrin overgrowth on an internal catheter be managed when there is no blood return from the implanted port?

Rare gene variants associated with side effects from paclitaxel

Researchers have identified the first genetic marker associated with severe neurologic toxicity from paclitaxel.

Immunosuppressives and anticancer drugs may reactivate Hepatitis B virus (HBV)

Immunosuppressives and anticancer drugs may reactivate Hepatitis B virus (HBV)

Chemotherapy or immunosuppressive treatment may reactive hepatitis B virus in patients previously infected with the virus.

Stat Consult Slideshows

Fluorouracil (5-FU)

This slideshow reviews fluorouracil (5-FU), indicated for palliative treatment of breast cancer, colorectal cancer, gastric cancer, and carcinoma of the pancreas; also adjuvant treatment of colorectal cancer.

Netupitant/Palonosetron (Akynzeo)

This slideshow reviews netupitant/palonosetron (Akynzeo), indicated for prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of cancer chemotherapy.

Bevacizumab (Avastin)

This slideshow reviews bevacizumab (Avastin), indicated for cervical cancer, in combination with paclitaxel and cisplatin or paclitaxel and topotecan in persistent, recurrent, or metastatic disease.

To view all content in our Stat Consult section, please click here.

Sign Up for Free e-newsletters

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs